FIA
EPIX

FNY Investment Advisers’s ESSA Pharma EPIX Stock Holding History

FNY Investment Advisers’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$44K – 792
2024
Q4 		$44K Buy
+25,000
New +$79.6K 0.02% 344

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return

FNY Investment Advisers's EPIX Position: Q1 2025 in Review

FNY Investment Advisers sold out of ESSA Pharma (EPIX) in Q1 2025, closing a stake of 25,000 shares — an estimated $44K sold.

FNY Investment Advisers first reported a position in EPIX in Q4 2024 and held it in 1 quarter. The position peaked at $44K in Q4 2024. 36 funds tracked by Wall St. Rank hold EPIX as of Q1 2025.

  • FNY Investment Advisers reported no remaining ESSA Pharma position as of Q1 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 25,000 ESSA Pharma shares in Q1 2025, an estimated $44K.
  • FNY Investment Advisers first reported a position in ESSA Pharma in Q4 2024 and held it in 1 quarter.
  • FNY Investment Advisers's ESSA Pharma position peaked at $44K in Q4 2024.
  • 36 funds tracked by Wall St. Rank held ESSA Pharma as of Q1 2025.

Based on FNY Investment Advisers's 13F filing for Q1 2025, filed 17 Apr 2025.